340B Advocacy Alliance Bulletin
In 2022, tax-exempt hospitals participating in the 340B Drug Pricing Program provided nearly $100 billion in total benefits to their communities, according to a new AHA report.
In a letter responding to HRSA’s information collection request regarding the expected costs of its 340B Rebate Model Pilot Program, the AHA said 340B hospitals indicated that the operational costs associated with the rebate model could range from $150,000 to over $500,000 per hospital.
The U.S. District Court for the District of Maine today issued an order denying preliminary injunctions requested by AbbVie and Novartis in legal challenges against the state’s law protecting 340B pricing for contract pharmacy arrangements.
AHA 340B Advocacy Alliance Bulletin - September 16, 2025.
AHA 340B Advocacy Alliance for September 8, 2025.
340B Advocacy Alliance Bulletin for September 5, 2025.
340B Advocacy Alliance Bulletin for September 3, 2025.
AHA comments to HRSA on proposed 340B rebate model program; register for Aug. 28 AHA call to discuss rebate model.
The AHA 340B Advocacy Alliance will host a call Aug. 28 at 12:30 p.m. ET to provide insights into the association’s comments to the Health Resources and Services Administration about the agency’s 340B Rebate Model Pilot Program, which will be shared with members next week.
The AHA, joined by several other national groups representing 340B hospitals, today urged the Health Resources and Services Administration to extend the timeline for stakeholder comments, agency consideration, and manufacturer rebate plan submissions for its 340B Rebate Model Pilot Program.